Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from UCLA. He was an American Cancer Society postdoctoral fellow at Stanford University from 1979-82 and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). He has since worked on the pathogenesis of hepatitis B and development of hepatocellular carcinoma on the cell and molecular levels. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became Professor of Pathology and Cell Biology. He also was director of a Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson went to Temple University as a Professor of Biology.  His work has been supported by NIH, industry and foundations, has more than 150 publications, and 180 abstracts. He was also the founding director of the Professional Science Master’s program in Biotechnology at Temple University. He is currently CSO of SFA Therapeutics, which is a Temple University spin-out of work from his lab.  SFA has won many awards for innovation and excellence and is currently in human clinical trials for gut microbiome-based treatments for autoimmune diseases and cancer. Dr. Feitelson has 17 patents and has been a consultant for more than 10 companies since the 1980s. Dr. Feitelson has also been active in teaching undergraduate and graduate courses including microbiology, virology, and critical thinking in biology (undergraduate), overseeing Biology of Cancer (undergraduate) and microbial biotechnology (graduate).  In the lab, he has mentored over 130 students since the mid-1980s, including 24 master’s students in Biology, 8 Ph.D. students in Biology, and 13 postdoctoral fellows.